Gilead Sciences, Inc. today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, the company's ...

Antiretroviral therapies work to help stop replication of the HIV virus in the body and can reduce the viral load to a point ...

HONG KONG SAR - Media OutReach Newswire – 12 November 2024 - Immuno Cure BioTech (" Immuno Cure "), a clinical-stage ...

Key targets include achieving 95 percent diagnosis, treatment, and viral load suppression among people living with HIV, as ...

The prevalence of liver steatosis was higher in people living with HIV compared with liver fibrosis, although both liver ...

Although sexually transmitted infections are still at an epidemic level in the US, scientists at the US Centers for Disease ...

Gilead Sciences, Inc. today announced the presentation of new research data from its innovative HIV treatment portfolio and pipeline, including a broad range of data on investigational and marketed ...

The study evaluated the efficacy and safety of Dovato in 230 antiretroviral treatment-naïve individuals with advanced HIV.

Encouraging findings with immunotherapy aiming at ART-free virological control A significant step towards functional cure of HIV infection ...

At eight weeks, the viral load of HIV declined in all participants and death of the infected cells was observed. Due to ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today ...